Dr Reddy’s bullish on China

by India Inc. Staff

With incipient regulatory changes in China on Indian drug imports, Dr Reddy’s Laboratories has identified about 70 products for the country to be launched in a few years and is also planning to build a new plant very close to the existing one.

Erez Israeli, COO, Dr Reddy’s, said the drug-maker is in the process of seeking necessary approvals from Chinese authorities for selling drugs including in oncology area there and is upgrading professional teams for the growth.

He said: “China is an important space for us and we see a major opportunity in China. As China opened, especially with the changes of regulations to the kind of products in terms of quality and cost-effective that we can build to China.

“We are upgrading our team in China and we are also going to build a new plant very close to the current plant that we have. So overall, very exciting opportunities.”

Recently, India has identified and shared with China a list of 380 products, including horticulture, textiles, chemicals and pharmaceutical products, as their shipments hold huge export potential.

2019-06-05T13:26:30+00:00June 5th, 2019|Uncategorized|

About the Author: India Inc. Staff